99 related articles for article (PubMed ID: 28447703)
1. Conserved effects and altered trafficking of Cetuximab antibodies conjugated to gold nanoparticles with precise control of their number and orientation.
García-Fernández L; Garcia-Pardo J; Tort O; Prior I; Brust M; Casals E; Lorenzo J; Puntes VF
Nanoscale; 2017 May; 9(18):6111-6121. PubMed ID: 28447703
[TBL] [Abstract][Full Text] [Related]
2. Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice.
Karmani L; Labar D; Valembois V; Bouchat V; Nagaswaran PG; Bol A; Gillart J; Levêque P; Bouzin C; Bonifazi D; Michiels C; Feron O; Grégoire V; Lucas S; Vander Borght T; Gallez B
Contrast Media Mol Imaging; 2013; 8(5):402-8. PubMed ID: 23740810
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 2.4 nm thiolate-protected gold nanoparticles conjugated to Cetuximab for targeting glioblastoma cancer cells via the EGFR.
Groysbeck N; Stoessel A; Donzeau M; da Silva EC; Lehmann M; Strub JM; Cianferani S; Dembélé K; Zuber G
Nanotechnology; 2019 May; 30(18):184005. PubMed ID: 30650397
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles.
Glazer ES; Massey KL; Zhu C; Curley SA
Surgery; 2010 Aug; 148(2):319-24. PubMed ID: 20541785
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles.
Curley SA; Cherukuri P; Briggs K; Patra CR; Upton M; Dolson E; Mukherjee P
J Exp Ther Oncol; 2008; 7(4):313-26. PubMed ID: 19227011
[TBL] [Abstract][Full Text] [Related]
6. Cancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticles.
Obaid G; Chambrier I; Cook MJ; Russell DA
Photochem Photobiol Sci; 2015 Apr; 14(4):737-47. PubMed ID: 25604735
[TBL] [Abstract][Full Text] [Related]
7. The physicochemical and biological characterization of a 24-month-stored nanocomplex based on gold nanoparticles conjugated with cetuximab demonstrated long-term stability, EGFR affinity and cancer cell death due to apoptosis.
Andrade LM; Martins EMN; Versiani AF; Reis DS; da Fonseca FG; Souza IP; Paniago RM; Pereira-Maia E; Ladeira LO
Mater Sci Eng C Mater Biol Appl; 2020 Feb; 107():110203. PubMed ID: 31761220
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.
Bouras A; Kaluzova M; Hadjipanayis CG
J Neurooncol; 2015 Aug; 124(1):13-22. PubMed ID: 25981803
[TBL] [Abstract][Full Text] [Related]
9. Targeted imaging of EGFR overexpressed cancer cells by brightly fluorescent nanoparticles conjugated with cetuximab.
Gao M; Su H; Lin G; Li S; Yu X; Qin A; Zhao Z; Zhang Z; Tang BZ
Nanoscale; 2016 Aug; 8(32):15027-32. PubMed ID: 27468980
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
[TBL] [Abstract][Full Text] [Related]
11. Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial.
von Tresckow B; Boell B; Eichenauer D; Beschorner D; Knop S; Goebeler ME; Chemnitz JM; Hallek M; Engert A; Huebel K
Leuk Lymphoma; 2014 Mar; 55(3):695-7. PubMed ID: 23713484
[No Abstract] [Full Text] [Related]
12. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells.
Patel J; Amrutiya J; Bhatt P; Javia A; Jain M; Misra A
J Microencapsul; 2018 Mar; 35(2):204-217. PubMed ID: 29542378
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
14. Lack of in vivo antibody dependent cellular cytotoxicity with antibody containing gold nanoparticles.
Ahmed M; Pan DW; Davis ME
Bioconjug Chem; 2015 May; 26(5):812-6. PubMed ID: 25879583
[TBL] [Abstract][Full Text] [Related]
15. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
Veluchamy JP; Spanholtz J; Tordoir M; Thijssen VL; Heideman DA; Verheul HM; de Gruijl TD; van der Vliet HJ
PLoS One; 2016; 11(6):e0157830. PubMed ID: 27314237
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.
Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R
Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
18. Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: results of in vitro and in vivo studies.
Barnea I; Haif S; Keshet R; Karaush V; Lev-Ari S; Khafif A; Shtabsky A; Yarden Y; Vexler A; Ben Yosef R
Head Neck; 2013 Mar; 35(3):399-407. PubMed ID: 22367849
[TBL] [Abstract][Full Text] [Related]
19. "Gold nanoparticles composite-folic acid conjugated graphene oxide nanohybrids" for targeted chemo-thermal cancer ablation: In vitro screening and in vivo studies.
Chauhan G; Chopra V; Tyagi A; Rath G; Sharma RK; Goyal AK
Eur J Pharm Sci; 2017 Jan; 96():351-361. PubMed ID: 27721039
[TBL] [Abstract][Full Text] [Related]
20. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
